Therapeutic Effects of Combination Therapy and Photobiomodulation Therapy on Retinal Regeneration

Introduction: Macular edema (ME) is produced by central extravascular inflammation of the macula subsequent to a major loss of visual action. Macular edema can happen at any phase of diabetic retinopathy, whether non-proliferative or proliferative retinopathy. Method and material: Articles were collected from four electronic databases PubMed, Google Scholar Web of Science from 2000 to 2022 and electronically to study the effects of macular laser grid photocoagulation on Diabetic macular edema or Cystoid macular edema through the keywords " macular laser photocoagulation ", " macular edema ", " Cystoid macular edema ", " Intravitreal pharmacotherapies ", " Antivascular endothelial growth factor “, were searched about 219 articles found in google scholar and 165 articles in PubMed, that   58 articles were included in the study. Result: In this study, the effects of various laser photocoagulation such as Focal and/or grid macular laser, subthreshold micropulse laser (SMPL), and Intravitreal pharmacotherapies (Corticosteroids such as triamcinolone acetonide, fluocinolone, Bevacizumab, and dexamethasone) on macular edema were investigated. A few studies had shown that the effects of corticosteroids are more effective than lasers, and a number of studies have found the effects of lasers and the combined effects of lasers with corticosteroids to be more effective. Also, some studies have also shown that the frequency and duration of follow-up and concentrations of intravitreal pharmacotherapies are effective in increasing visual outcomes. Conclusion: The results of studies showed that although corticosteroids have side effects, the combined effects of corticosteroids with subthreshold micropulse laser are effective in increasing visual acuity (VA) and central macular thickness (CMT)

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy

Antibody-based cancer immunotherapy has become a powerful asset in the arsenal against malignancies. In this regard, bispecific antibodies (BsAbs) are a ground-breaking novel approach in the therapy of cancers. Recently, BsAbs have represented a significant advancement in improving clinical outcomes. BsAbs are designed to target two different antigens specifically. Over a hundred various BsAb forms currently exist, and more are constantly being manufactured. An antagonistic regulator of T cell activation is cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or CD152, a second counter-receptor for the B7 family of co-stimulatory molecules was introduced in 1996 by Professor James P. Allison and colleagues. Contrary to the explosive success of dual immune checkpoint blockade for treating cancers, a major hurdle still yet persist is that immune-related adverse events (irAEs) observed by combining immune checkpoint inhibitors (ICIs) or monoclonal antibodies such as ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). A promising strategy to overcome this hurdle is using BsAbs. This article will summarize BsAbs targeting CTLA-4, their applications in cancer immunotherapy, and relevant clinical trial advances. We will also discuss the pre-clinical rationale for using these BsAbs, and provide the current landscape of the field